Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Volume 25, Issue 4
  5. Article
Volume 25, Issue 4
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Obesity is now recognised as an emerging public health problem across the globe. Its incidence has been growing in the last two decades. Furthermore, as per the obesity treatment guidelines, a comprehensive approach that incorporates behavioural treatment, medications, lifestyle modifications, and/or bariatric surgery is the best way to manage weight. A novel dual agonist of Glucose-dependent insulinotropic peptide (GIP) and Glucagon-like peptide -1 (GLP-1) receptors, Tirzepatide, was recently approved for the management of obesity. Tirzepatide manages blood sugar levels and enhances weight loss more than GLP-1 receptor agonists.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303319530240703111013
2024-07-11
2025-05-23

  • From This Site

    /content/journals/emiddt/10.2174/0118715303319530240703111013
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChaudharyM. SharmaP. Abdominal obesity in India: Analysis of the national family health survey-5 (2019–2021) data.Lancet Reg. Health Southeast Asia20231410020810.1016/j.lansea.2023.100208 37492420
     [Google Scholar]
  2. GuptaR.D. TamannaN. SiddikaN. HaiderS.S. ApuE.H. HaiderM.R. Obesity and abdominal obesity in indian population: findings from a nationally representative study of 698,286 participants.Epidemiologia20234216317210.3390/epidemiologia4020017 37218876
     [Google Scholar]
  3. KalraS. KapoorN. VermaM. ShaikhS. DasS. JacobJ. SahayR. Defining and diagnosing obesity in India: A call for advocacy and action.J. Obes.2023202311310.1155/2023/4178121 38026823
     [Google Scholar]
  4. MulitaF. LampropoulosC. KehagiasD. VerrasG.I. TchabashviliL. KaplanisC. LiolisE. IliopoulosF. PerdikarisI. KehagiasI. Long-term nutritional deficiencies following sleeve gastrectomy: A 6-year single-centre retrospective study.Przegl. Menopauz.202120417017610.5114/pm.2021.110954 35069068
     [Google Scholar]
  5. VerrasG.I. MulitaF. LampropoulosC. KehagiasD. CurwenO. AntzoulasA. PanagiotopoulosI. LeivaditisV. KehagiasI. Risk factors and management approaches for staple line leaks following sleeve gastrectomy: A single-center retrospective study of 402 patients.J. Pers. Med.2023139142210.3390/jpm13091422 37763189
     [Google Scholar]
  6. IdreesZ. CancarevicI. HuangL. FDA-approved pharmacotherapy for weight loss over the last decade.Cureus2022149e2926210.7759/cureus.29262 36277516
     [Google Scholar]
  7. ChakhtouraM. HaberR. GhezzawiM. RhayemC. TcheroyanR. MantzorosC.S. Pharmacotherapy of obesity: An update on the available medications and drugs under investigation.EClin.lMed.20235810188210.1016/j.eclinm.2023.101882 36992862
     [Google Scholar]
  8. WaddenT.A. ChaoA.M. MachineniS. KushnerR. ArdJ. SrivastavaG. HalpernB. ZhangS. ChenJ. BunckM.C. AhmadN.N. ForresterT. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial.Nat. Med.202329112909291810.1038/s41591‑023‑02597‑w 37840095
     [Google Scholar]
  9. ChavdaV.P. AjabiyaJ. TeliD. BojarskaJ. ApostolopoulosV. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review.Molecules20222713431510.3390/molecules27134315 35807558
     [Google Scholar]
  10. WilsonJ.M. NikooienejadA. RobinsD.A. RoellW.C. RiesmeyerJ.S. HauptA. DuffinK.L. TaskinenM.R. RuotoloG. The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.Diabetes Obes. Metab.202022122451245910.1111/dom.14174 33462955
     [Google Scholar]
  11. HeiseT. DeVriesJ.H. UrvaS. LiJ. PrattE.J. ThomasM.K. MatherK.J. KaranikasC.A. DunnJ. HauptA. MilicevicZ. CoskunT. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes.Diabetes Care2023465998100410.2337/dc22‑1710 36857477
     [Google Scholar]
  12. JastreboffA.M. AronneL.J. AhmadN.N. WhartonS. ConneryL. AlvesB. KiyosueA. ZhangS. LiuB. BunckM.C. StefanskiA. Tirzepatide once weekly for the treatment of obesity.N. Engl. J. Med.2022387320521610.1056/NEJMoa2206038 35658024
     [Google Scholar]
  13. GarveyW.T. FriasJ.P. JastreboffA.M. le RouxC.W. SattarN. AizenbergD. MaoH. ZhangS. AhmadN.N. BunckM.C. BenabbadI. ZhangX.M. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet20234021040261362610.1016/S0140‑6736(23)01200‑X 37385275
     [Google Scholar]
  14. FarzamK. PatelP. Tirzepatide.Treasure Island, FLStatPearls Publishing2023120
     [Google Scholar]
  15. GallwitzB. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.Front. Endocrinol.202213100404410.3389/fendo.2022.1004044 36313764
     [Google Scholar]
  16. KanekoS. Tirzepatide: A novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes.TouchREV. Endocrinol.20221811019
     [Google Scholar]
  17. Obstructive sleep apnea master protocol GPIF: A study of tirzepatide (LY3298176) in participants with obstructive sleep apnea (SURMOUNT-OSA).NCT054120042024Available from: https://clinicaltrials.gov/study/NCT05412004?term=surmount%20OSA&intr=tirzepatide%20&rank=1 (assessed on 28.02.2024).
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303319530240703111013
Loading
A New Drug for Obesity: Tirzepatide
Endocr Metab Immune Disord Drug Targets 25, 267 (2025); https://doi.org/10.2174/0118715303319530240703111013
/content/journals/emiddt/10.2174/0118715303319530240703111013
/content/journals/emiddt/10.2174/0118715303319530240703111013
Loading

Data & Media loading...


  • Article Type:     Editorial
Keyword(s): anti-obesity medicine; GIP; GLP-1 receptor agonists; Obesity; tirzepatide; weight management

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test